Israeli medical company Gamida Cell will move forward with testing its second pipeline product – NiCord, for treatment of blood cancer and other blood-related conditions. The trials are expected to show results within 6 months. This announcement comes two weeks after the company’s announcement of its contact with pharmaceutical giant Pfizer, with intention of commercializing Gamida Cell’s flagship product – StemEX.
Related posts
A Promising Treatment For Trauma-Induced Fibromyalgia
March 23, 2023
Generative AI Startup Helps Developers Test Code Logic
March 23, 2023
Cream Cheese And Cheddar Cheese – Made From Chickpeas
March 22, 2023
$8M For Startup That Digitizes The Construction Supply Chain
March 22, 2023
Facebook comments